Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Фракталкин и сердечно-сосудистые заболевания
Фракталкин и сердечно-сосудистые заболевания
Алиева А.М., Алмазова И.И., Пинчук Т.В. и др. Фракталкин и сердечно-сосудистые заболевания. Consilium Medicum. 2020; 22 (5): 83–86. DOI:10.26442/20751753.2020.5.200186
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Фракталкин (или хемокин CX3CL1) относится к семейству хемокинов и представляет собой белок с молекулярной массой 95 кДа, рассматривается в качестве маркера дисфункции эндотелия. Согласно имеющимся данным современных исследований, фракталкин можно позиционировать как маркер активности воспалительных процессов разного генеза; как важный прогностический показатель при хронической сердечной недостаточности не только ишемической, но и неишемической этиологии и маркер контроля эффективности проводимого лечения у этой группы больных; как предиктор неблагоприятных исходов и показатель эффективности чрескожного коронарного вмешательства у пациентов с острым инфарктом миокарда, ценный прогностический маркер для больных со стабильной стенокардией (с гемодинамически значимым стенозом коронарных артерий), а также предиктор тромботических и тромбоэмболических осложнений при фибрилляции предсердий. В настоящее время весьма перспективным является исследование возможностей медикаментозного воздействия на фракталкин (CX3CL1) и его рецептор (CX3CR1) с целью патогенетической терапии сердечно-сосудистых заболеваний.
Ключевые слова: фракталкин, атеросклеротические сердечно-сосудистые заболевания, хроническая сердечная недостаточность, острый инфаркт миокарда, левый желудочек.
Key words: fractalkine, atherosclerotic cardiovascular diseases, chronic heart failure, acute myocardial infarction, left ventricle.
Ключевые слова: фракталкин, атеросклеротические сердечно-сосудистые заболевания, хроническая сердечная недостаточность, острый инфаркт миокарда, левый желудочек.
________________________________________________
Key words: fractalkine, atherosclerotic cardiovascular diseases, chronic heart failure, acute myocardial infarction, left ventricle.
Полный текст
Список литературы
1. Cherepanov D, Bentley TGK, Hsiao W et al. Real-world Cardiovascular Disease Burden in Patients With Atherosclerotic Cardiovascular Disease: A Comprehensive Systematic Literature Review. Curr Med Res Opin 2018; 34 (3): 459–73. DOI: 10.1080/03007995.2017.1401529
2. Guo Y, Apostalakis S, Blann AD, Lip GYH. Plasma CX3CL1 Levels and Long-Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 2014; 38 (3): 204–11. DOI: 10.1159/000365841
3. Кухтина Н.Б., Арефьева Т.И., Рулева Н.Ю. и др. Пептидные фрагменты хемокинового домена фракталкина: влияние на миграцию моноцитов человека. Биоорганич. химия. 2012; 38 (6): 660–6.
[Kukhtina N.B., Aref'eva T.I., Ruleva N.Iu. et al. Peptidnye fragmenty khemokinovogo domena fraktalkina: vliianie na migratsiiu monotsitov cheloveka. Bioorganich. khimiia. 2012; 38 (6): 660–6 (in Russian).]
4. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993–8001.
5. Hildemann SK, Schulz C, Fraccarollo D et al. Fractalkine Promotes Platelet Activation and Vascular Dysfunction in Congestive Heart Failure. Thromb Haemost 2014; 111 (4): 725–35. DOI: 10.1160/TH13-08-0640
6. Skoda M, Stangret A, Szukiewicz D. Fractalkine and Placental Growth Factor: A Duet of Inflammation and Angiogenesis in Cardiovascular Disorders. Cytokine Growth Factor Rev 2018; 39: 116–23. DOI: 10.1016/j.cytogfr.2017.12.001
7. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine. J Immunol 2007; 179 (11): 7478–87.
8. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15–21.
9. Schulz C, Schäfer A, Stolla M et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764–73.
10. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17–24.
11. Ji CL, Nomi A, Li B et al. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. Int Heart J 2019; 60 (3): 701–7. DOI: 10.1536/ihj.18-422
12. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011; 1813: 2026–35.
13. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin 2013; 34: 1251–6.
14. Zhou JJ, Wang YM, Lee VWS et al. DEC205-DC Targeted DNA Vaccine Against CX3CR1 Protects Against Atherogenesis in Mice. PLoS One 2018; 13 (4): e0195657. DOI: 10.1371/journal.pone.0195657
15. Stolla M, Pelisek J, von Brühl ML et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS ONE 2012; 7: e43572.
16. Li J, Guo Y, Luan X et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012; 76: 2167–73.
17. Richter B, Koller L, Hohensinner PJ et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220–7.
18. Patel A, Jagadesham VP, Porter KE et al. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008; 36: 20–7.
19. Rius C, Company C, Piqueras L et al. Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 2013; 68: 177–86.
20. Wanling Xuan, Yulin Liao, Baihe Chen et al. Detrimental Effect of Fractalkine on Myocardial Ischaemia and Heart Failure. Cardiovasc Res 2011; 92 (3): 385–93. DOI: 10.1093/cvr/cvr221
21. Полунина Е.А., Воронина Л.П., Севостьянова И.В. и др. Уровень фракталкина при хронической сердечной недостаточности различной степени тяжести. Кардиология. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473
[Polunina E.A., Voronina L.P., Sevostyanova I.V. et al. Fractalkine level in chronic heart failure of varying severity. Cardiology. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473 (in Russian).]
22. Лопина Н.А., Журавлева Л.В. Уровни фракталкина и асимметричного диметиларгинина у больных ишемической болезнью сердца в зависимости от наличия сахарного диабета 2-го типа и характера поражения коронарных артерий. Научный результат. Медицина и фармация. 2016; 2 (3): 11–7.
[Lopina N.A., Zhuravleva L.V. Levels of fraktalkin and asymmetric dimethylarginin in patients with ischemic heart disease depending on the presence of diabetes of the 2rd type and character of damage of coronary arteries. Research Result. Medicine and Pharmacy. 2016; 2 (3): 11–7. DOI: 10.18413/2313-8955-2016-2-3-11-17 [(in Russian).]
23. Yao K, Zhang S, Lu H et al. Changes in fractalkine in patients with ST-elevation myocardial infarction. Coronary Artery Disease 2015; 26 (6): 516–20. DOI: 10.1097/MCA.0000000000000273
2. Guo Y, Apostalakis S, Blann AD, Lip GYH. Plasma CX3CL1 Levels and Long-Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 2014; 38 (3): 204–11. DOI: 10.1159/000365841
3. Kukhtina N.B., Aref'eva T.I., Ruleva N.Iu. et al. Peptidnye fragmenty khemokinovogo domena fraktalkina: vliianie na migratsiiu monotsitov cheloveka. Bioorganich. khimiia. 2012; 38 (6): 660–6 (in Russian).
4. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993–8001.
5. Hildemann SK, Schulz C, Fraccarollo D et al. Fractalkine Promotes Platelet Activation and Vascular Dysfunction in Congestive Heart Failure. Thromb Haemost 2014; 111 (4): 725–35. DOI: 10.1160/TH13-08-0640
6. Skoda M, Stangret A, Szukiewicz D. Fractalkine and Placental Growth Factor: A Duet of Inflammation and Angiogenesis in Cardiovascular Disorders. Cytokine Growth Factor Rev 2018; 39: 116–23. DOI: 10.1016/j.cytogfr.2017.12.001
7. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine. J Immunol 2007; 179 (11): 7478–87.
8. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15–21.
9. Schulz C, Schäfer A, Stolla M et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764–73.
10. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17–24.
11. Ji CL, Nomi A, Li B et al. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. Int Heart J 2019; 60 (3): 701–7. DOI: 10.1536/ihj.18-422
12. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011; 1813: 2026–35.
13. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin 2013; 34: 1251–6.
14. Zhou JJ, Wang YM, Lee VWS et al. DEC205-DC Targeted DNA Vaccine Against CX3CR1 Protects Against Atherogenesis in Mice. PLoS One 2018; 13 (4): e0195657. DOI: 10.1371/journal.pone.0195657
15. Stolla M, Pelisek J, von Brühl ML et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS ONE 2012; 7: e43572.
16. Li J, Guo Y, Luan X et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012; 76: 2167–73.
17. Richter B, Koller L, Hohensinner PJ et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220–7.
18. Patel A, Jagadesham VP, Porter KE et al. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008; 36: 20–7.
19. Rius C, Company C, Piqueras L et al. Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 2013; 68: 177–86.
20. Wanling Xuan, Yulin Liao, Baihe Chen et al. Detrimental Effect of Fractalkine on Myocardial Ischaemia and Heart Failure. Cardiovasc Res 2011; 92 (3): 385–93. DOI: 10.1093/cvr/cvr221
21. Polunina E.A., Voronina L.P., Sevostyanova I.V. et al. Fractalkine level in chronic heart failure of varying severity. Cardiology. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473 (in Russian).
22. Lopina N.A., Zhuravleva L.V. Levels of fraktalkin and asymmetric dimethylarginin in patients with ischemic heart disease depending on the presence of diabetes of the 2rd type and character of damage of coronary arteries. Research Result. Medicine and Pharmacy. 2016; 2 (3): 11–7. DOI: 10.18413/2313-8955-2016-2-3-11-17 [(in Russian).
23. Yao K, Zhang S, Lu H et al. Changes in fractalkine in patients with ST-elevation myocardial infarction. Coronary Artery Disease 2015; 26 (6): 516–20. DOI: 10.1097/MCA.0000000000000273
2. Guo Y, Apostalakis S, Blann AD, Lip GYH. Plasma CX3CL1 Levels and Long-Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 2014; 38 (3): 204–11. DOI: 10.1159/000365841
3. Кухтина Н.Б., Арефьева Т.И., Рулева Н.Ю. и др. Пептидные фрагменты хемокинового домена фракталкина: влияние на миграцию моноцитов человека. Биоорганич. химия. 2012; 38 (6): 660–6.
[Kukhtina N.B., Aref'eva T.I., Ruleva N.Iu. et al. Peptidnye fragmenty khemokinovogo domena fraktalkina: vliianie na migratsiiu monotsitov cheloveka. Bioorganich. khimiia. 2012; 38 (6): 660–6 (in Russian).]
4. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993–8001.
5. Hildemann SK, Schulz C, Fraccarollo D et al. Fractalkine Promotes Platelet Activation and Vascular Dysfunction in Congestive Heart Failure. Thromb Haemost 2014; 111 (4): 725–35. DOI: 10.1160/TH13-08-0640
6. Skoda M, Stangret A, Szukiewicz D. Fractalkine and Placental Growth Factor: A Duet of Inflammation and Angiogenesis in Cardiovascular Disorders. Cytokine Growth Factor Rev 2018; 39: 116–23. DOI: 10.1016/j.cytogfr.2017.12.001
7. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine. J Immunol 2007; 179 (11): 7478–87.
8. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15–21.
9. Schulz C, Schäfer A, Stolla M et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764–73.
10. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17–24.
11. Ji CL, Nomi A, Li B et al. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. Int Heart J 2019; 60 (3): 701–7. DOI: 10.1536/ihj.18-422
12. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011; 1813: 2026–35.
13. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin 2013; 34: 1251–6.
14. Zhou JJ, Wang YM, Lee VWS et al. DEC205-DC Targeted DNA Vaccine Against CX3CR1 Protects Against Atherogenesis in Mice. PLoS One 2018; 13 (4): e0195657. DOI: 10.1371/journal.pone.0195657
15. Stolla M, Pelisek J, von Brühl ML et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS ONE 2012; 7: e43572.
16. Li J, Guo Y, Luan X et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012; 76: 2167–73.
17. Richter B, Koller L, Hohensinner PJ et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220–7.
18. Patel A, Jagadesham VP, Porter KE et al. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008; 36: 20–7.
19. Rius C, Company C, Piqueras L et al. Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 2013; 68: 177–86.
20. Wanling Xuan, Yulin Liao, Baihe Chen et al. Detrimental Effect of Fractalkine on Myocardial Ischaemia and Heart Failure. Cardiovasc Res 2011; 92 (3): 385–93. DOI: 10.1093/cvr/cvr221
21. Полунина Е.А., Воронина Л.П., Севостьянова И.В. и др. Уровень фракталкина при хронической сердечной недостаточности различной степени тяжести. Кардиология. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473
[Polunina E.A., Voronina L.P., Sevostyanova I.V. et al. Fractalkine level in chronic heart failure of varying severity. Cardiology. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473 (in Russian).]
22. Лопина Н.А., Журавлева Л.В. Уровни фракталкина и асимметричного диметиларгинина у больных ишемической болезнью сердца в зависимости от наличия сахарного диабета 2-го типа и характера поражения коронарных артерий. Научный результат. Медицина и фармация. 2016; 2 (3): 11–7.
[Lopina N.A., Zhuravleva L.V. Levels of fraktalkin and asymmetric dimethylarginin in patients with ischemic heart disease depending on the presence of diabetes of the 2rd type and character of damage of coronary arteries. Research Result. Medicine and Pharmacy. 2016; 2 (3): 11–7. DOI: 10.18413/2313-8955-2016-2-3-11-17 [(in Russian).]
23. Yao K, Zhang S, Lu H et al. Changes in fractalkine in patients with ST-elevation myocardial infarction. Coronary Artery Disease 2015; 26 (6): 516–20. DOI: 10.1097/MCA.0000000000000273
________________________________________________
2. Guo Y, Apostalakis S, Blann AD, Lip GYH. Plasma CX3CL1 Levels and Long-Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. Cerebrovasc Dis 2014; 38 (3): 204–11. DOI: 10.1159/000365841
3. Kukhtina N.B., Aref'eva T.I., Ruleva N.Iu. et al. Peptidnye fragmenty khemokinovogo domena fraktalkina: vliianie na migratsiiu monotsitov cheloveka. Bioorganich. khimiia. 2012; 38 (6): 660–6 (in Russian).
4. Garton KJ, Gough PJ, Blobel CP et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993–8001.
5. Hildemann SK, Schulz C, Fraccarollo D et al. Fractalkine Promotes Platelet Activation and Vascular Dysfunction in Congestive Heart Failure. Thromb Haemost 2014; 111 (4): 725–35. DOI: 10.1160/TH13-08-0640
6. Skoda M, Stangret A, Szukiewicz D. Fractalkine and Placental Growth Factor: A Duet of Inflammation and Angiogenesis in Cardiovascular Disorders. Cytokine Growth Factor Rev 2018; 39: 116–23. DOI: 10.1016/j.cytogfr.2017.12.001
7. Mizutani N, Sakurai T, Shibata T et al. Dose-dependent differential regulation of cytokine secretion from macrophages by Fractalkine. J Immunol 2007; 179 (11): 7478–87.
8. Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15–21.
9. Schulz C, Schäfer A, Stolla M et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007; 116: 764–73.
10. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17–24.
11. Ji CL, Nomi A, Li B et al. Increased Plasma Soluble Fractalkine in Patients with Chronic Heart Failure and Its Clinical Significance. Int Heart J 2019; 60 (3): 701–7. DOI: 10.1536/ihj.18-422
12. Butoi ED, Gan AM, Manduteanu I et al. Cross talk between smooth muscle cells and monocytes/activated monocytes via CX3CL1/CX3CR1 axis augments expression of pro-atherogenic molecules. Biochim Biophys Acta 2011; 1813: 2026–35.
13. Apostolakis S, Spandidos D. Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway. Acta Pharmacol Sin 2013; 34: 1251–6.
14. Zhou JJ, Wang YM, Lee VWS et al. DEC205-DC Targeted DNA Vaccine Against CX3CR1 Protects Against Atherogenesis in Mice. PLoS One 2018; 13 (4): e0195657. DOI: 10.1371/journal.pone.0195657
15. Stolla M, Pelisek J, von Brühl ML et al. Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS ONE 2012; 7: e43572.
16. Li J, Guo Y, Luan X et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012; 76: 2167–73.
17. Richter B, Koller L, Hohensinner PJ et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220–7.
18. Patel A, Jagadesham VP, Porter KE et al. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease. Eur J Vasc Endovasc Surg 2008; 36: 20–7.
19. Rius C, Company C, Piqueras L et al. Critical role of fractalkine (CX3CL1) in cigarette smoke-induced mononuclear cell adhesion to the arterial endothelium. Thorax 2013; 68: 177–86.
20. Wanling Xuan, Yulin Liao, Baihe Chen et al. Detrimental Effect of Fractalkine on Myocardial Ischaemia and Heart Failure. Cardiovasc Res 2011; 92 (3): 385–93. DOI: 10.1093/cvr/cvr221
21. Polunina E.A., Voronina L.P., Sevostyanova I.V. et al. Fractalkine level in chronic heart failure of varying severity. Cardiology. 2018; 58 (8S): 54–7. DOI: 10.18087/cardio.2473 (in Russian).
22. Lopina N.A., Zhuravleva L.V. Levels of fraktalkin and asymmetric dimethylarginin in patients with ischemic heart disease depending on the presence of diabetes of the 2rd type and character of damage of coronary arteries. Research Result. Medicine and Pharmacy. 2016; 2 (3): 11–7. DOI: 10.18413/2313-8955-2016-2-3-11-17 [(in Russian).
23. Yao K, Zhang S, Lu H et al. Changes in fractalkine in patients with ST-elevation myocardial infarction. Coronary Artery Disease 2015; 26 (6): 516–20. DOI: 10.1097/MCA.0000000000000273
Авторы
А.М. Алиева*1, И.И. Алмазова2, Т.В. Пинчук1, Е.В. Резник1, А.М. Рахаев3, И.Г. Никитин1
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия;
3 ФКУ «Главное бюро медико-социальной экспертизы по Кабардино-Балкарской республике» Минтруда России, Нальчик, Россия
*amisha_alieva@mail.ru
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia;
3 Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic, Nalchik, Russia
*amisha_alieva@mail.ru
1 ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва, Россия;
3 ФКУ «Главное бюро медико-социальной экспертизы по Кабардино-Балкарской республике» Минтруда России, Нальчик, Россия
*amisha_alieva@mail.ru
________________________________________________
1 Pirogov Russian National Research Medical University, Moscow, Russia;
2 National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia;
3 Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic, Nalchik, Russia
*amisha_alieva@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.